-
1 Comment
Tandem Diabetes Care, Inc is currently in a long term uptrend where the price is trading 6.3% above its 200 day moving average.
From a valuation standpoint, the stock is 99.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 10.8.
Tandem Diabetes Care, Inc's total revenue rose by 55.0% to $168M since the same quarter in the previous year.
Its net income has increased by 541.0% to $17M since the same quarter in the previous year.
Finally, its free cash flow fell by 12.2% to $11M since the same quarter in the previous year.
Based on the above factors, Tandem Diabetes Care, Inc gets an overall score of 4/5.
Sector | Healthcare |
---|---|
Industry | Medical Devices |
Exchange | F |
CurrencyCode | EUR |
ISIN | US8753722037 |
Beta | 1.53 |
---|---|
Market Cap | 964M |
PE Ratio | None |
Target Price | 133.5 |
Dividend Yield | None |
Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for TD5A.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025